Peter S N van Rossum
Overview
Explore the profile of Peter S N van Rossum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
1178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Laarhoven H, Verhoeven R, van Berge Henegouwen M, Haj Mohammad N, van Hillegersberg R, Slingerland M, et al.
EClinicalMedicine
. 2025 Feb;
80:103067.
PMID: 39911244
Background: Recent studies in patients with resectable adenocarcinoma of the esophagus or gastroesophageal junction (GEJ)-Neo-AEGIS and ESOPEC-have explored the comparison of neoadjuvant chemoradiotherapy (nCRT) with chemotherapy, with conflicting results. To...
2.
Webster A, Fog L, Hall E, van Rossum P, Nevens D, Montay-Gruel P, et al.
Clin Transl Radiat Oncol
. 2025 Feb;
51:100895.
PMID: 39898327
Survey-based research is increasingly used in radiation oncology, yet survey-based research methodology is often unfamiliar in the field. This guideline offers comprehensive instructions for conducting survey-based research in radiation oncology,...
3.
Damen P, Peters M, Hobbs B, Chen Y, Titt U, Nout R, et al.
Int J Radiat Oncol Biol Phys
. 2025 Jan;
PMID: 39755214
Purpose: A detrimental association between radiation-induced lymphopenia (RIL) and oncologic outcomes in patients with esophageal cancer has been established. However, an optimal metric for RIL remains undefined but is important...
4.
Kroese T, Bronzwaer S, van Rossum P, van Laarhoven H, van Hillegersberg R
Curr Oncol Rep
. 2025 Jan;
27(1):30-36.
PMID: 39753813
Purpose Of The Review: This narrative review aims to provide an overview of recently completed randomized trials and expert consensus recommendations, and their implications for clinical practice and future trial...
5.
van Rossum P, Wolfhagen N, Damhuis R, Belderbos J
J Thorac Oncol
. 2024 Nov;
19(11):e74-e77.
PMID: 39510717
No abstract available.
6.
Chen Y, Chu Y, van Rossum P, Grassberger C, Lin S, Mohan R, et al.
Adv Radiat Oncol
. 2024 Sep;
9(10):101579.
PMID: 39258141
Purpose: Radiation-induced lymphopenia (RIL) is common during chemoradiation therapy. Severe lymphopenia is associated with reduced survival. Proton beam therapy (PBT), with its substantially more compact dose distributions, spares circulating lymphocytes...
7.
Palma D, Giuliani M, Correa R, Schneiders F, Harrow S, Guckenberger M, et al.
BMC Palliat Care
. 2024 Sep;
23(1):223.
PMID: 39244532
Background: Emerging randomized data, mostly from phase II trials, have suggested that patients with oligometastatic cancers may benefit from ablative treatments such as stereotactic ablative radiotherapy (SABR). However, phase III...
8.
Clinical Translation of a Deep Learning Model of Radiation-Induced Lymphopenia for Esophageal Cancer
Hu Z, Mohan R, Chu Y, Wang X, van Rossum P, Chen Y, et al.
Int J Part Ther
. 2024 Sep;
13:100624.
PMID: 39228692
Purpose: Radiation-induced lymphopenia is a common immune toxicity that adversely impacts treatment outcomes. We report here our approach to translate a deep-learning (DL) model developed to predict severe lymphopenia risk...
9.
van Rossum P, Wolfhagen N, van Bockel L, Coremans I, van Es C, van der Geest A, et al.
J Thorac Oncol
. 2024 Jul;
19(11):1550-1563.
PMID: 39067700
Introduction: Stereotactic body radiotherapy (SBRT) has firmly established its role in stage I NSCLC. Clinical trial results may not fully apply to real-world scenarios. This study aimed to uncover the...
10.
Damen P, Lin S, van Rossum P
Front Oncol
. 2024 Jul;
14:1448658.
PMID: 39015501
No abstract available.